Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Oct 2018 10:37

RNS Number : 6159E
Sinclair Pharma PLC
19 October 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SINCLAIR PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

TOSCAFUND ASSET MANAGEMENT LLP

City and country of registered office (if applicable)

LONDON, ENGLAND

4. Full name of shareholder(s) (if different from 3.)v

Name

TOSCA MID CAP

TOSCA OPPORTUNITY

THE PEGASUS FUND LIMITED

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

17/10/2018

6. Date on which issuer notified (DD/MM/YYYY):

19/10/2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0%

N/A

0%

503,768,952

Position of previous notification (if

applicable)

11.24%

N/A

11.24%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0033856740

0

0

0

0

SUBTOTAL 8. A

0

0%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

N/A

N/A

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

N/A

N/A

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

None

 

Place of completion

LONDON, ENGLAND

Date of completion

19/10/2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMLBLTMBJBMFP
Date   Source Headline
28th Mar 20177:15 amRNSHardman Research: Much more streamlined
27th Mar 201710:30 amRNSAppointment of Joint Broker
22nd Mar 20175:29 pmRNSHolding(s) in Company
21st Mar 20177:00 amRNSPreliminary Results
21st Mar 20177:00 amRNSSettlement Agreement with Sinclair Pharma plc
17th Jan 20179:27 amRNSHardman Research: Demanding targets exceeded
17th Jan 20177:00 amRNSPre-Close Trading Update
5th Jan 20177:15 amRNSNotification of full year trading update
17th Nov 201610:39 amRNSDirector/PDMR Shareholding
17th Nov 201610:36 amRNSAdditional Listing
8th Nov 20169:08 amRNSHardman Research: Poised for a long term uplift
8th Nov 20167:05 amRNSHardman Research: Poised for a long term uplift
18th Oct 20165:55 pmRNSHolding(s) in Company
13th Oct 20164:46 pmRNSHolding(s) in Company
5th Oct 20167:00 amRNSDirector/PDMR Shareholding
3rd Oct 20163:56 pmRNSHolding(s) in Company
30th Sep 20162:29 pmRNSTotal Voting Rights
29th Sep 20162:24 pmRNSHolding(s) in Company
28th Sep 20162:23 pmRNSAdditional Listing
27th Sep 20164:14 pmRNSDirector/PDMR Shareholding
27th Sep 20164:12 pmRNSDirector/PDMR Shareholding
26th Sep 20165:04 pmRNSAdditional Listing
22nd Sep 20162:02 pmRNSHolding(s) in Company
21st Sep 20167:00 amRNSHalf-year Report
1st Sep 20167:00 amRNSRestructuring Programme and Board Change
22nd Aug 20167:00 amRNSNotice of Results
19th Jul 20167:00 amRNSTrading Statement
2nd Jun 20167:00 amRNSPresenting at Jefferies Healthcare Conference
31st May 20167:00 amRNSDirector Dealing
24th May 20169:52 amRNSPurchase of shares by Chief Financial Officer
23rd May 20167:00 amRNSDirector Dealing
20th May 201611:43 amRNSOption Awards
20th May 201610:16 amRNSDirector Dealings
20th May 20167:00 amRNSUS Collaboration and Positive Trading Update
19th May 20164:35 pmRNSUS Collaboration and Positive Trading Update
19th May 20162:15 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th May 201612:50 pmRNSForm 8.3 - Sinclair Pharma PLC
19th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th May 201611:24 amRNSForm 8.3 - Sinclair Pharma plc
17th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
16th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
13th May 20161:35 pmRNSForm 8.3 - Sinclair Pharma plc
12th May 201612:40 pmRNSForm 8.3 - Sinclair Pharma plc
11th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
10th May 20162:13 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
10th May 20161:56 pmRNSForm 8.3 - Sinclair Pharma plc
9th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201612:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
6th May 201611:25 amPRNForm 8.3 - Sinclair Pharma Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.